WEST Search History

DATE: Monday, July 21, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=ADJ		
L20	L19 and ribozyme	51	L20
L19	l16 not l17	401	L19
L18	l16 not l17L16 and newgard	15	L18
L17	L16 and newgard	15	L17
L16	antisense and glycolytic and hexokinase	416	L16
L15	L14 and l13	458	L15
L14	glycolytic	3757	L14
L13	l11 or l10	562	L13
L12	l11 or l10L11	93	L12
L11	l6 and l9	88	L11
L10	l8 and l9	554	L10
L9	cancer or tumor	74018	L9
L8	l2 and l1	660	L8
L7	l2 and l1L6	0	L7
L6	l3 and l1	94	L6
L5	l3 and l2	4821	L5
L4	L3 and l1	94	L4
L3	ribozyme	5245	L3
L2	antisense or anti-sense	19468	L2
L1	hexokinase	2141	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1805SXM

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:55:41 ON 21 JUL 2003

=> file medline caplus embase biosis scisearch biotechno
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:56:09 ON 21 JUL 2003

FILE 'CAPLUS' ENTERED AT 12:56:09 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:56:09 ON 21 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:56:09 ON 21 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 12:56:09 ON 21 JUL 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'BIOTECHNO' ENTERED AT 12:56:09 ON 21 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s hexokinase
L1 31106 HEXOKINASE

=> s antisense or anti-sense
L2 124697 ANTISENSE OR ANTI-SENSE

=> l1 and l2
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and l2
L3 95 L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 52 DUP REM L3 (43 DUPLICATES REMOVED)

=> d 1-52 ti

L4 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
TI Nucleic acid probes useful for gene expression monitoring and a variety of genetic analyses

L4 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses

L4 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Expression profiles of rat genes involved in restenosis and atherosclerosis and use in diagnosis and therapy

L4 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

TI Methods and compositions for the detection and treatment of multiple sclerosis

L4 ANSWER 5 OF 52 MEDLINE on STN DUPLICATE 2
TI The putative glutamate receptor 1.1 (AtGLR1.1) functions as a regulator of carbon and nitrogen metabolism in Arabidopsis thaliana.

L4 ANSWER 6 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Suppression of fructokinase encoded by LeFRK2 in tomato stem inhibits growth and causes wilting of young leaves

L4 ANSWER 7 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Effects of carbohydrate starvation on gene expression in citrus root

L4 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Treatment of respiratory and lung diseases with **antisense** oligonucleotides and a bronchodilating agent

L4 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

L4 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of a 11.66-kilodalton human **hexokinase** -like protein and their therapeutic uses

L4 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Human 9.02-kDa **hexokinase** like protein and its cDNA and therapeutic use

L4 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of a 10.78-kilodalton human **hexokinase** -like protein and their therapeutic uses

L4 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of a 10.01-kilodalton human **hexokinase** sequence homolog and their therapeutic uses

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of a 10.78-kilodalton human **hexokinase** -like protein and their therapeutic uses

L4 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI cDNA and protein sequence of a novel human protein 9.68 and their uses in drug screening, diagnosis and therapeutics

L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells

L4 ANSWER 17 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Expression of the thylakoid membrane localized PPF1 in transgenic Arabidopsis affects chloroplast/development

L4 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2003 ACS on STNDUPLICATE 3
TI Glucose and mannose regulate the expression of a major sucrose synthase gene in Arabidopsis via **hexokinase**-dependent mechanisms

L4 ANSWER 19 OF 52 MEDLINE on STN DUPLICATE 4
TI The effect of exogenous sugars on the control of flux by adenosine 5'-diphosphoglucose pyrophosphorylase in potato tuber discs.

L4 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2003 ACS on STNDUPLICATE 5
TI The tomato **hexokinase** LeHXK1 cloning, mapping, expression

pattern and phylogenetic relationships

L4 ANSWER 21 OF 52 MEDLINE on STN DUPLICATE 6
TI Potato **hexokinase** 2 complements transgenic Arabidopsis plants deficient in **hexokinase** 1 but does not play a key role in tuber carbohydrate metabolism.

L4 ANSWER 22 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Regulation of photosynthesis during Arabidopsis leaf development in continuous light

L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of 11 kDa human **hexokinase**-like protein and therapeutic use thereof

L4 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Cloning, expression, sequence and therapeutic use of a novel human **hexokinase** 50365

L4 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of 10 kDa human **hexokinase** sequence homolog and therapeutic use thereof

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Arrest of proliferation of highly glycolytic tumors by **antisense** oligonucleotides of **hexokinase** cDNA

L4 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method for influencing pollen development by modifying sucrose metabolism

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA of 12 kDa human **hexokinase** sequence homolog and therapeutic use thereof

L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Moss genes from Physcomitrella patens encoding proteins involved in the synthesis of carbohydrates

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Engineering of replication selective adenoviruses with tumor-associated antigen promoter for use in cancer therapy

L4 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Large-scale monitoring of expression patterns of p53-regulated gene and analysis of p53 gene function

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protein and cDNA sequences of a novel human **hexokinase** 14 and therapeutic use thereof

L4 ANSWER 33 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Microarray analysis of PTP1B **antisense**-treated ob/ob mice reveals downregulation of genes involved in the gluconeogenesis pathway.

L4 ANSWER 34 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Sucrose and light regulation of a cold-inducible UDP-glucose pyrophosphorylase gene via a **hexokinase**-independent and abscisic acid-insensitive pathway in Arabidopsis

L4 ANSWER 35 OF 52 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STNDUPLICATE 7
TI Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: Applications to breast cancer.

L4 ANSWER 36 OF 52 MEDLINE on STN DUPLICATE 8
TI Control of carbon partitioning and photosynthesis by the triose phosphate/phosphate translocator in transgenic tobacco plants (Nicotiana tabacum L.). I. Comparative physiological analysis of tobacco plants with **antisense** repression and overexpression of the triose phosphate/phosphate translocator.

L4 ANSWER 37 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Alternative interpretations of the oligonucleotide transport literature: insights from nature

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Cancer diagnosis and therapy based on expression levels of p53-regulated genes

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Plant galactose dehydrogenase

L4 ANSWER 40 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STNDUPLICATE 9
TI Sucrose-starch conversion in heterotrophic tissues of plants

L4 ANSWER 41 OF 52 MEDLINE on STN DUPLICATE 10
TI **Antisense** repression of **hexokinase** 1 leads to an overaccumulation of starch in leaves of transgenic potato plants but not to significant changes in tuber carbohydrate metabolism.

L4 ANSWER 42 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI **Antisense** oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Induction of the activity of glycolytic enzymes correlates with enhanced hydrolysis of sucrose in the cytosol of transgenic potato tubers

L4 ANSWER 44 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Arrest of proliferation of highly glycolytic tumors upon Type II **hexokinase** down regulation via an **antisense** RNA approach.

L4 ANSWER 45 OF 52 MEDLINE on STN DUPLICATE 11
TI Compensation of decreased triose phosphate/phosphate translocator activity by accelerated starch turnover and glucose transport in transgenic tobacco.

L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Altering plant responses to sugar concentrations by altering **hexokinase** concentrations

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
TI Methods and compositions for inhibiting **hexokinase** in mammalian cells and their use for treating diabetes

L4 ANSWER 48 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI Developmental changes of enzymes involved in conversion of sucrose to hexose-phosphate during early tuberisation of potato

L4 ANSWER 49 OF 52 MEDLINE on STN DUPLICATE 12
TI **Hexokinase** as a sugar sensor in higher plants.

L4 ANSWER 50 OF 52 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
TI EXPRESSION OF OXIDATIVE-PHOSPHORYLATION GENES IN RENAL TUMORS AND TUMORAL CELL-LINES

L4 ANSWER 51 OF 52 MEDLINE on STN DUPLICATE 13
TI Evidence of the crucial role of sucrose synthase for sink strength using transgenic potato plants (Solanum tuberosum L.).

L4 ANSWER 52 OF 52 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STNDUPLICATE 14
TI Ribozyme-mediated attenuation of pancreatic .beta.-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion.

=> d 9 24 25 26 28 32 33 44 47 ab

L4 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L4 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The invention provides isolated nucleic acids mols., designated 50365 nucleic acid mols., which encode novel **hexokinase** members. The cDNA sequence and the encoded amino acid sequence of a novel human **hexokinase** 50365 (clone Fbh50365FL) are disclosed. Tissue-specific expression profile of the **hexokinase** 50365 is presented. Recombinant expression of the **hexokinase** 50365 in bacterial cells and COS cells is also reported. The invention also provides **antisense** nucleic acid mols., recombinant expression vectors contg. 50365 nucleic acid mols., host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 50365 gene has been introduced or disrupted. The invention still further provides isolated 50365 proteins, fusion proteins, antigenic peptides and anti-50365 antibodies. Diagnostic methods utilizing compns. of the invention are also provided.

L4 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The invention provides protein and cDNA sequences for 10 kDa novel human

protein cloned from fetal brain, and its protein which have similar expression pattern with human **hexokinase** 12. The invention also relates to constructing **hexokinase** sequence homolog gene expression vectors to prep. recombinant **hexokinase** sequence homolog using prokaryote or eukaryote cells. Methods of expressing and prepg. recombinant **hexokinase** sequence homolog and its antibody are described. Methods of using **hexokinase** sequence homolog gene or protein products for the treatment of various kinds of diseases, such as cancer, blood diseases, HIV infection, immune diseases and inflammation are also disclosed.

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The present invention relates to a method of inhibiting the proliferation of tumor cells using **antisense** polynucleotides or oligonucleotides. Tumor cells having a highly glycolytic phenotype can be inhibited with an **antisense** mol. that hybridizes with a nucleic acid encoding a **hexokinase**. The present invention also relates to recombinant nucleic acid mols. useful for regulating transcription and translation and which can contain an **antisense** mol. The present invention also relates to pharmaceutical prepns. contg. **antisense** mols.

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The invention provides cDNA sequences for 12 kDa novel human protein cloned from fetal brain, and its protein sequences which have sequence homol. to a known **hexokinase**. The invention also relates to constructing **hexokinase** 12 gene expression vectors to prep. recombinant **hexokinase** 12 protein using prokaryote or eukaryote cells. Methods of expressing and prepg. recombinant **hexokinase** 12 protein and its antibody are described. Methods of using **hexokinase** 12 gene or protein products for the treatment of various kinds of diseases, such as cancer, blood diseases, HIV infection, immune diseases and inflammation are also disclosed.

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The invention provides protein and cDNA sequences of a novel human protein, designated as "**hexokinase** 14", which has similar gene expression pattern with known human **hexokinase**-12. The invention relates to expression of **hexokinase** 14 in E.coli BL21(DE3)plySs transfected with plasmid pET-28(+). The invention also relates to prepn. of antibody against **hexokinase** 14. The invention further relates to the uses of the **hexokinase** 14 fragment as probes in diagnosis, and in treatment of **hexokinase** 14-related diseases (such as malignant tumors, growth and development disorders, blood disease, immune disorder, HIV infection, or inflammation).

L4 ANSWER 33 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

L4 ANSWER 44 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AB The enzymic activities of **hexokinase** in mammalian cells are inhibited by providing (1) proteins that stimulate the prodn. of trehalose-6-phosphate and their resp. genes; (2) **hexokinase** -specific ribozymes and genes encoding such constructs; and (3) agents that competitively reduce **hexokinase** activity, e.g., by displacing **hexokinase** from mitochondria, and their resp. genes. The latter group of agents includes inactive **hexokinase** and fragments thereof that retain mitochondrial binding functions and **hexokinase**-glucokinase chimeras that further substitute glucokinase activity for **hexokinase** activity. Mammalian cells contg. such **hexokinase** inhibitors, methods of making such cells and various in vitro and in vivo methods of using the engineered cells

with reduced **hexokinase** activity for treating diabetes are also described. An expression vector contg. the strong promoter/enhancer of human cytomegalovirus was prepd. for the expression of the N-terminal (1-455) domain of rat **hexokinase** I in RIN 1046-38 neuroendocrine cells, which domain is competent to bind to mitochondria and dislodge endogenous **hexokinase**. Other methods for inhibiting **hexokinase** in mammalian cells by expression of chimeric **hexokinase**/glucokinase, trehalose-6-phosphate synthase, **hexokinase** ribozymes, or by site-specific mutagenesis of an allele of the **hexokinase** I gene were also demonstrated.

=> d 33 44 47

L4 ANSWER 33 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:440470 BIOSIS
DN PREV200100440470
TI Microarray analysis of PTP1B **antisense**-treated ob/ob mice reveals downregulation of genes involved in the gluconeogenesis pathway.
AU Waring, Jeffrey F. (1); Ciurlionis, Rita (1); Gum, Rebecca J. (1); Trevillyan, James M. (1); Zinker, Bradley A. (1); Jirousek, Michael R. (1); Ulrich, Roger G. (1)
CS (1) Abbott Park, IL USA
SO Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A230. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DT Conference
LA English
SL English

L4 ANSWER 44 OF 52 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:184331 BIOSIS
DN PREV199900184331
TI Arrest of proliferation of highly glycolytic tumors upon Type II **hexokinase** down regulation via an **antisense** RNA approach.
AU Mathupala, Saroj P.; Pedersen, Peter L.
CS Dep. Biol. Chem., Johns Hopkins Univ. Sch. Med., Baltimore, MD 21205 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 22.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American Association for Cancer Research
. ISSN: 0197-016X.
DT Conference
LA English

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:499256 CAPLUS
DN 127:187510
TI Methods and compositions for inhibiting **hexokinase** in mammalian cells and their use for treating diabetes
IN Newgard, Christopher B.; Han, He-ping; Thigpen, Anice E.; Normington, Karl D.
PA Board of Regents, University of Texas System, USA; Betagene, Inc.; Newgard, Christopher B.; Han, He-Ping; Thigpen, Anice E.; Normington, Karl D.
SO PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9726357	A1	19970724	WO 1997-US787	19970117
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5854067	A	19981229	US 1996-588983	19960119
	AU 9718315	A1	19970811	AU 1997-18315	19970117
	AU 714852	B2	20000113		
	EP 877810	A1	19981118	EP 1997-903845	19970117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-588983		19960119		
	WO 1997-US787		19970117		